Pfizer and BioNTech Collaborate to Co-Develop BNT162 Against COVID-19

 Pfizer and BioNTech Collaborate to Co-Develop BNT162 Against COVID-19

Pfizer and BioNTech Collaborate to Co-Develop BNT162 Against COVID-19

Shots:

  • The companies collaborate to accelerate the development of BioNTech’s BNT162, which is anticipated to enter clinical studies by the end of Apr’2020. The alliance will leverage the expertise and resources of both companies to co-develop mRNA-based vaccine candidate globally (Ex- China)
  • The collaboration follows 2018 agreement signed b/w the companies to develop mRNA-based vaccines against influenza
  • The companies have implemented a material transfer and collaboration agreement that enable them to start working together immediately and will finalize financial terms over the next few weeks

Click here to­ read full press release/ article | Ref: Pfizer | Image: The Economic Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post